Francis Ayuk

Impact of anti-T-lymphocyte globulin dosing on graft versus host disease in matched sibling peripheral blood stem cell transplantation.

Comparison of anti-human T cell globulins on immune reconstitution and early infections after autologous transplant in patients with multiple sclerosis.

Outcomes of allogeneic transplantation in blast-phase myeloproliferative neoplasms: one-third achieve long-term survival.

Busulfan pharmacokinetics in adults - a real-world evaluation of intra-individual variability and the impact of obesity and deferasirox.

Multicenter validation of the newly developed Concise Objectifiable Risk Evaluation (CORE) score also confirms its ability to complement the Hematopoietic Cell Comorbidity Index (HCT-CI).

A new therapeutic frontier: CD19-targeting CAR-T cell therapy in rheumatoid arthritis: a concise report.

Haploidentical transplantation with post-transplant cyclophosphamide is not inferior to 9/10-MUD transplantation with ATG in patients with myeloid malignancies.

Gastrin for the treatment of acute graft-versus-host disease of the stomach.

Interindividual HLA Evolutionary Divergence in Single HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation for Malignant Hematological Disorders: A Report on Behalf of the Cellular Therapy and Immunobiology Working Party of the EBMT

Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma

Safety and efficacy of the ROCK-2-inhibitor Belumosudil in cGvHD treatment - a retrospective, German-Swiss multicenter real-world data analysis.

Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST

Young unrelated donors confer a survival advantage for patients with myeloid malignancies compared to older siblings

The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD

A novel approach to refractory idiopathic inflammatory myopathy: CD19 CAR T-cell therapy-case report and literature review.

Young unrelated donors confer a survival advantage for patients with myeloid malignancies compared to older siblings.

T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany.

Sequential versus standard conditioning in untreated MDS patients with blasts undergoing allogeneic HSCT.

Reconstructing skeletal homeostasis through allogeneic hematopoietic stem cell transplantation in myelofibrosis.

Grade I acute graft-vs-host disease: Treat or not?

Busulfan pharmacokinetics in adults – a real-world evaluation of intra-individual variabil-ity and the impact of obesity and deferasirox

Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis

Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.

Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis

A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD

A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD